Agios Pharmaceuticals, Inc.
AGIOAgios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.: Table 1
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
4
Next Catalyst
Mar 15, 2026
5wMarket Overview
Stock performance and market intelligence
4 upcoming, 0 past
Tebapivat Phase 2 Results Expected
Primary completion for Tebapivat trial (NCT05490446) in Myelodysplastic Syndromes
SourceFDA PDUFA Date Pyrukynd (standard)
For pyruvate kinase deficiency. NDA filing. Extracted from SEC filing: 8-K
SourceTebapivat Phase 2 Results Expected
Primary completion for Tebapivat trial (NCT06924970) in Sickle Cell Disease
SourceFDA PDUFA Date Undisclosed drug candidate (standard)
NDA filing. Extracted from SEC filing: 8-K
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Regulatory & News
Approvals, filings, and latest developments